Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company focused on developing peptide-based drugs to address unmet medical needs. The company has recently gained attention due to a significant development in its product pipeline. On March 18, 2026, Roger Song from Jefferies set a price target of $121 for NASDAQ:PTGX, suggesting a potential price increase of approximately 23.75% from its current price of $97.78.
A key factor contributing to this optimistic outlook is the recent FDA approval of ICOTYDE™ (icotrokinra), an innovative interleukin-23 (IL-23) receptor antagonist. This approval is a major milestone for Protagonist Therapeutics, as ICOTYDE is the first and only IL-23R targeted oral peptide designed to treat moderate-to-severe plaque psoriasis in both adults and pediatric patients aged 12 and older. The approval was supported by four phase 3 studies involving 2,500 patients, all of which met their primary endpoints and demonstrated a favorable safety profile.
The FDA approval of ICOTYDE not only enhances Protagonist Therapeutics' product portfolio but also has significant financial implications. The company will receive a $50 million milestone payment and is eligible for 6% to 10% royalties on sales. Additionally, Protagonist Therapeutics could earn up to $580 million in future milestone payments, further strengthening its financial position.
Despite the positive news, PTGX's stock price has seen a slight decrease of 0.14%, currently priced at $97.09. The stock has fluctuated between a low of $90.58 and a high of $99.44 today. Over the past year, PTGX has reached a high of $99.45 and a low of $39.60, reflecting its volatile nature. The company's market capitalization is approximately $6.2 billion, with a trading volume of 1,948,990 shares on the NASDAQ exchange.
